TRCT
OVID icon

Tower Research Capital (TRC)’s Ovid Therapeutics OVID Stock Holding History

Tower Research Capital (TRC)’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,676
Closed -$17.4K – 5435
2025
Q4 		$17.4K Buy
10,676
+8,332
+355% +$12.8K ﹤0.01% 3206
2025
Q3 		$3.05K Sell
2,344
-49,176
-95% -$42.6K ﹤0.01% 4550
2025
Q2 		$17K Buy
51,520
+27,674
+116% +$8.34K ﹤0.01% 3765
2025
Q1 		$7.44K Buy
23,846
+14,006
+142% +$8.61K ﹤0.01% 3952
2024
Q4 		$9.19K Buy
9,840
+1,539
+19% +$1.72K ﹤0.01% 3927
2024
Q3 		$9.79K Sell
8,301
-5,876
-41% -$6.14K ﹤0.01% 3832
2024
Q2 		$10.9K Sell
14,177
-9,958
-41% -$27.7K ﹤0.01% 4117
2024
Q1 		$73.6K Buy
24,135
+19,752
+451% +$66.1K ﹤0.01% 2016
2023
Q4 		$14.1K Buy
4,383
+346
+9% +$1.18K ﹤0.01% 3905
2023
Q3 		$15.5K Buy
4,037
+549
+16% +$1.97K ﹤0.01% 3611
2023
Q2 		$11.4K Sell
3,488
-1,822
-34% -$6.19K ﹤0.01% 3975
2023
Q1 		$14K Sell
5,310
-15,006
-74% -$35.6K ﹤0.01% 3902
2022
Q4 		$38K Sell
20,316
-11,749
-37% -$20K ﹤0.01% 2546
2022
Q3 		$59K Buy
32,065
+14,062
+78% +$29.4K ﹤0.01% 3014
2022
Q2 		$39K Buy
18,003
+14,010
+351% +$33.9K ﹤0.01% 3125
2022
Q1 		$13K Buy
3,993
+212
+6% +$667 ﹤0.01% 3992
2021
Q4 		$12K Sell
3,781
-3,710
-50% -$12.7K ﹤0.01% 4310
2021
Q3 		$25K Buy
7,491
+3,967
+113% +$14.5K ﹤0.01% 3529
2021
Q2 		$14K Sell
3,524
-5,914
-63% -$23.3K ﹤0.01% 4184
2021
Q1 		$38K Sell
9,438
-33,119
-78% -$110K ﹤0.01% 3357
2020
Q4 		$98K Buy
42,557
+2,011
+5% +$9.37K ﹤0.01% 2373
2020
Q3 		$233K Buy
40,546
+38,421
+1,808% +$257K ﹤0.01% 2436
2020
Q2 		$16K Sell
2,125
-8,842
-81% -$41.4K ﹤0.01% 3791
2020
Q1 		$33K Sell
10,967
-8,096
-42% -$27.3K ﹤0.01% 1480
2019
Q4 		$79K Buy
+19,063
New +$60.2K 0.01% 1075
2019
Q3 		– Sell
-3,264
Closed -$6K – 4401
2019
Q2 		$6K Sell
3,264
-6,269
-66% -$11.2K ﹤0.01% 2856
2019
Q1 		$17K Buy
9,533
+240
+3% +$600 ﹤0.01% 2365
2018
Q4 		$23K Buy
9,293
+2,920
+46% +$13.3K ﹤0.01% 1826
2018
Q3 		$36K Buy
+6,373
New +$48.3K ﹤0.01% 1967
2018
Q2 		– Sell
-724
Closed -$5K – 3946
2018
Q1 		$5K Buy
+724
New +$5.86K ﹤0.01% 2715
2017
Q4 		– Sell
-246
Closed -$2K – 3869
2017
Q3 		$2K Buy
+246
New +$2.05K ﹤0.01% 3582

Other funds holding OVID

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Tower Research Capital (TRC)'s OVID Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Ovid Therapeutics (OVID) in Q1 2026, closing a stake of 10,676 shares — an estimated $17.4K sold.

Tower Research Capital (TRC) first reported a position in OVID in Q3 2017 and held it in 31 quarters. The position peaked at $233K in Q3 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Ovid Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 10,676 Ovid Therapeutics shares in Q1 2026, an estimated $17.4K.
  • Tower Research Capital (TRC) first reported a position in Ovid Therapeutics in Q3 2017 and held it in 31 quarters.
  • Tower Research Capital (TRC)'s Ovid Therapeutics position peaked at $233K in Q3 2020.
  • 103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.